DCN Dx Expert Insights
oleh DCN Dx
Where IVD Studies Lose Enrollment: Respiratory and STI Lessons from…
Tentang podcast ini
DCN Dx Expert Insights is a podcast for teams developing and commercializing in vitro diagnostics. Each episode brings together scientists, clinical researchers, regulatory specialists, manufacturing experts, and industry leaders to examine the decisions that determine whether an IVD program reaches the market.
Topics include assay development, clinical evidence, regulatory strategy, biospecimens, manufacturing, scale-up, product development, and commercialization.
Subscribe to Expert Insights on Spotify, Apple Podcasts, or your preferred platform, and visit dcndx.com for additional tools and resources.
LISTEN AND FOLLOW
Spotify: https://open.spotify.com/show/16GcmTI4U7dhzKSQe0mUhO
Apple Podcasts: https://podcasts.apple.com/us/podcast/dcn-dx-expert-insights/id1793226272
Subscribe on YouTube: https://www.youtube.com/channel/UCgMr7XR64b1Q1_0nG-X8b1Q?sub_confirmation=1
MORE FROM DCN DX
Explore IVD articles, podcast transcripts, and technical resources: https://dcndx.com/insights/
Learn more about DCN Dx: https://dcndx.com/
Discuss your IVD program with our team: https://dcndx.com/contact/
Episode
20 episode terbaru dari 25
- Where IVD Studies Lose Enrollment: Respiratory and STI Lessons from the Sites · 49 mnt · Musim 3 Episode 15Why do IVD clinical studies lose enrollment opportunities? Learn how testing and treatment timing, home testing, and clinic workflows affect patient recruitment in respiratory…
- What Breakthrough Designation Does and Doesn't Do for an IVD · 34 mntWhat does FDA Breakthrough Device designation mean for an in vitro diagnostic (IVD)? Learn what it takes to qualify, what evidence supports a request, and how designation can…
- After the Court Vacated FDA’s LDT Rule: What IVD Developers Still Need to Get Right · 57 mnt · Musim 3 Episode 15After a federal court vacated FDA’s final rule for laboratory-developed tests (LDTs) in 2025, did the LDT pathway fully reopen? Not exactly. In Season 3, Episode 15 of Expert…
- Wellness or Medical Device? FDA's 2026 Wellness Guidance and the WHOOP Warning Letter · 44 mnt · Musim 3 Episode 11In July 2025, FDA told WHOOP that its Blood Pressure Insights feature was an unauthorized medical device. WHOOP disputed FDA’s position and kept selling it. In January 2026…
- Planning Around a Respiratory Season That Won’t Hold Still · 39 mnt · Musim 3 Episode 11Why respiratory trials built on last year’s calendar are falling behind, and what sponsors need to do differently to catch the season on time. Respiratory disease patterns have…
- Before the Protocol: What Sponsors Miss About Sites and Human Factors · 57 mnt · Musim 3 Episode 10A site management CEO and a human factors specialist on what sponsors miss before a diagnostic study ever starts. Most conversations about IVD clinical research happen from the…
- Where Programs Fail: Bridging Assay Development and Manufacturing for Lateral Flow · 42 mnt · Musim 3 Episode 9Your lateral flow assay performs at the bench. Will that performance hold on the manufacturing line? Manufacturing introduces conditions the assay may not have faced at the…
- Off the Patchwork: What a Connected Platform Lets a CRO Do for Sponsors · 44 mnt · Musim 3 Episode 8Many IVD clinical studies still run on a patchwork of disconnected tools: a file share here, a spreadsheet there, a separate system for clinical operations and another for the…
- Stuck in a Holding Pattern: The IVDR Revision and Planning for Two Markets at Once · 36 mnt · Musim 3 Episode 7The 2026 IVDR transition deadlines are here, and a lot of IVD companies are sitting still. After the European Commission proposed a revision to the regulation in December 2025…
- QMSR Is in Effect: What IVD Manufacturers Still Need to Do · 36 mnt · Musim 3 Episode 6In this episode, Emily Friedland, VP of Clinical Research at DCN Dx, talks with two guests who come at QMSR from different directions: the regulatory strategy side and the…
- Specimen Strategy Is Development Strategy (And Why "We'll Source It Later" Fails) · 36 mnt · Musim 3 Episode 5Specimen strategy is one of the most common sources of avoidable delay in IVD development. Teams that defer specimen decisions until after the evidence plan is set tend to…
- Automation Beyond the Strip: Building Repeatable Rapid Test Production with KinBio · 16 mnt · Musim 3 Episode 4As rapid diagnostic programs transition from R&D to scaled production, small sources of variation can quickly become major risks. In this episode of Expert Insights, Mitzi…
- Point-of-Care in 2025: Lateral Flow Grew Up. Where Will the Technology Go Next? · 43 mnt · Musim 3 Episode 3In this episode of Expert Insights, DCN Dx’s Mitzi Rettinger speaks with Dr. Pat Vaughan, DCN Dx’s Chief Operating Officer, about what point-of-care really meant in 2025, how…
- The DCN Dx Model: Integration, Scale, and What Comes Next with DCN Dx CEO Charlie Mamrak · 17 mnt · Musim 3 Episode 2A DCN Dx Expert Insights conversation with Charlie Mamrak, CEO at DCN Dx, hosted by Mitzi Rettinger. Most IVD programs don’t lose months because a single experiment failed. They…
- Predetermined Change Control Plans (PCCPs) for AI-Enabled IVDs · 26 mnt · Musim 3 Episode 1A DCN Dx Expert Insights conversation with Dan Simpson, RAC, Director of Regulatory Affairs at DCN Dx, and Emily Friedland, VP of Clinical Research at DCN Dx. FDA’s…
- BioDot on Making LFAs Manufacturable: What Strong Lines Look Like Before You Scale · 34 mnt · Musim 2 Episode 10BioDot’s Director of Sales for the Americas, Rob Rich, joins Mitzi to talk about the practical side of lateral flow manufacturing. They cover where precision dispensing and web…
- K-One on Gold: Turning Surface Chemistry into Real LFA Performance with Kimialys · 35 mnt · Musim 2 Episode 9Surface chemistry on gold nanoparticles is one of the quiet levers that decides how your lateral flow test performs in the real world. In this episode of Expert Insights, host…
- Rugged by Design: Making LFA Work in the Clinic, at Home, and in Production with Kellie LaRochelle, CEO, Imagene Technology · 32 mnt · Musim 2 Episode 6Lateral flow succeeds when real-world constraints drive design: ease of use, ruggedness, and affordability. Few guests can speak to those tradeoffs from the bench, the exam room…
- Making Quantitative Work: Practical Guidance from Cytiva’s Klaus Hochleitner · 24 mnt · Musim 2 Episode 7Quantitative formats are no longer niche. They’re fast becoming standard in respiratory panels, chronic disease monitoring, and decentralized clinical trials. But building a…
- Hype or Help? How to Evaluate Generative AI in Diagnostics with Jeremy Elser, Ph.D., Head of Science Operations at Palantir · 31 mnt · Musim 2 Episode 5How do you separate signal from noise when it comes to AI in diagnostics? In this episode of Expert Insights, host Mitzi Rettinger sits down with Jeremy Elser, Ph.D.—a…








